US Pharma MarketingPhenomix is working on genetic tests to identify which patients may benefit from GLP-1s and which will be intolerant of the medications. “I remember when we decided the internet was going to cure everything, and it didn’t…it came with a certain set of problems,” said Mark Bagnall, CEO of Phenomix Sciences. GLP-1s are having a similar moment, he says. GLP-1s have been transformative for many; by 2025, more than 30 million Americans were taking them for weight loss. However, some scientists are sounding the alarm about overconfidence in the “one treatment for all” story. Eli Lilly became the first pharmaceutical…
“I remember when we decided the internet was going to cure everything, and it didn’t…it came with a certain set of problems,” said Mark Bagnall, CEO of Phenomix Sciences. GLP-1s are having a similar moment, he says. GLP-1s have been transformative for many; by 2025, more than 30 million Americans were taking them for weight…
The post Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market appeared first on Drug Discovery and Development.
Source: Drug Discovery & Development